Synergy Pharmaceuticals (SGYP) PT Nearly Doubled at Cantor Fitzgerald
Tweet Send to a FriendGet Alerts SGYP Hot Sheet
Price: $5.08 +0.59%
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 29
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 29
Trade SGYP Now!
Cantor Fitzgerald raised its price target on Buy-rated Synergy Pharmaceuticals (NASDAQ: SGYP) from $7 to $13 following positive top-line results from its Phase IIb/III chronic constipation (CC) trial of plecanatide.
The firm comments, "While details were not disclosed since the company is attempting to present late-breaker data at DDW, management indicated that (1) there was a nice dose response effect; and (2) the highest dose in the trial (3 mg) demonstrated a 19% responder rate versus 10.7% for placebo, which was statistically significant (p=0.009). Also, the drug led to a mean increase of +2.13 complete spontaneous bowel movements (CSBMs) over the 12-week period. Impressively, the incidence of diarrhea at the highest dose was 9.7% vs. 1.3% in placebo (severity not disclosed). The 3.0 mg dose had weaker results in the Phase IIa trial, which management attributed to more severe baseline constipation."
The firm's new price target anticipates a potential takeout scenario for the company.
For an analyst ratings summary and ratings history on Synergy Pharmaceuticals click here. For more ratings news on Synergy Pharmaceuticals click here.
Shares of Synergy Pharmaceuticals are up 14.6 percent mid-day to $6.03.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "While details were not disclosed since the company is attempting to present late-breaker data at DDW, management indicated that (1) there was a nice dose response effect; and (2) the highest dose in the trial (3 mg) demonstrated a 19% responder rate versus 10.7% for placebo, which was statistically significant (p=0.009). Also, the drug led to a mean increase of +2.13 complete spontaneous bowel movements (CSBMs) over the 12-week period. Impressively, the incidence of diarrhea at the highest dose was 9.7% vs. 1.3% in placebo (severity not disclosed). The 3.0 mg dose had weaker results in the Phase IIa trial, which management attributed to more severe baseline constipation."
The firm's new price target anticipates a potential takeout scenario for the company.
For an analyst ratings summary and ratings history on Synergy Pharmaceuticals click here. For more ratings news on Synergy Pharmaceuticals click here.
Shares of Synergy Pharmaceuticals are up 14.6 percent mid-day to $6.03.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- Jefferies Lifts Numbers on Diana Shipping (DSX) Post Q1
- Leerink Swann Bullish on Insmed (INSM); Raises PT to $22
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, RumorsRelated Entities
Cantor Fitzgerald
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
